Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bolt Biotherapeutics (BOLT) Non-Current Assets (2019 - 2025)

Historic Non-Current Assets for Bolt Biotherapeutics (BOLT) over the last 7 years, with Q3 2025 value amounting to $29.4 million.

  • Bolt Biotherapeutics' Non-Current Assets fell 4357.41% to $29.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $158.8 million, marking a year-over-year decrease of 2125.72%. This contributed to the annual value of $48.8 million for FY2024, which is 972.34% down from last year.
  • Per Bolt Biotherapeutics' latest filing, its Non-Current Assets stood at $29.4 million for Q3 2025, which was down 4357.41% from $37.2 million recorded in Q2 2025.
  • Bolt Biotherapeutics' Non-Current Assets' 5-year high stood at $118.6 million during Q4 2021, with a 5-year trough of $29.4 million in Q3 2025.
  • Its 5-year average for Non-Current Assets is $64.1 million, with a median of $54.1 million in 2023.
  • Its Non-Current Assets has fluctuated over the past 5 years, first skyrocketed by 45973.75% in 2021, then plummeted by 5355.78% in 2022.
  • Bolt Biotherapeutics' Non-Current Assets (Quarter) stood at $118.6 million in 2021, then plummeted by 53.56% to $55.1 million in 2022, then fell by 1.79% to $54.1 million in 2023, then decreased by 9.72% to $48.8 million in 2024, then crashed by 39.68% to $29.4 million in 2025.
  • Its Non-Current Assets was $29.4 million in Q3 2025, compared to $37.2 million in Q2 2025 and $43.4 million in Q1 2025.